資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/31663
|
| 標題: | Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia |
| 作者: | Lee, Ching-Chi
Wang, Jiun-Ling
Lee, Chung-Hsun
Hung, Yuan-Pin
Hong, Ming-Yuan
Tang, Hung-Jen
Ko, Wen-Chien |
| 貢獻者: | Madou Sin Lau Hosp, Dept Internal Med, Div Crit Care Med
Chang Jung Christian Univ, Coll Hlth Sci, Grad Inst Med Sci
Natl Cheng Kung Univ,Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med
Natl Cheng Kung Univ, Coll Med, Dept Med
Natl Cheng Kung Univ Hosp, Dept Emergency Med
Tainan Hosp, Minist Hlth & Welf, Dept Internal Med
Chi Mei Med Ctr, Dept Med
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr |
| 關鍵字: | De-escalation
Bacteremia
Escherichia coli
Klebsiella species
Proteus mirabilis |
| 日期: | 2017-09 |
| 上傳時間: | 2018-11-30 15:52:01 (UTC+8) |
| 出版者: | Elsevier Science Bv |
| 摘要: | The clinical benefits of an antimicrobial de-escalation strategy were compared with those of a noswitch strategy in bacteremic patients. Adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia treated empirically using broad-spectrum betalactams, including third-generation cephalosporins (GCs), fourth-GC or carbapenems, were treated definitively with first-or second-GCs (de-escalation group), the same regimens as empirical antibiotics (no-switch group), or antibiotics with a broader-spectrum than empirical antibiotics (escalation group). The eligible 454 adults were categorized as the de-escalation (231 patients, 50.9%), no-switch (177, 39.0%), and escalation (46, 10.1%) groups. Patients with de-escalation therapy were more often female, had less critical illness and fatal comorbidity, and had a higher survival rate than patients in the other two groups. After propensity score matching in the de-escalation and no-switch groups, critical illness at onset (Pitt bacteremia score = 4; 16.5% vs. 12.7%; P = 0.34) or day 3 (2.5% vs. 2.5%; P = 1.00), fatal comorbidity (16.5% vs. 21.5%; P = 0.25), time to defervescence (4.6 vs. 4.7 days; P = 0.89), hospital stays (11.5 vs. 10.3 days; P = 0.13) and 4-week crude mortality rate (4.4% vs. 4.4%; P = 1.00) were similar. However, lower antibiotic cost (mean: 212.1 vs. 395.6 US$, P < 0.001) and fewer complications of bloodstream infections due to resistant pathogens (0% vs. 5.1%, P = 0.004) were observed in the de-escalation group. De-escalation to narrower-spectrum cephalosporins is safe and cost-effective for adults with community-onset EKP bacteremia stabilized by empirical broad-spectrum beta-lactams. (C) 2017 Elsevier B. V. and International Society of Chemotherapy. All rights reserved. |
| 關聯: | International Journal of Antimicrobial Agents, v.50, n.3, pp.371-376 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1155 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
